TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27775810
Drug: Humanized nursing
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Humanized nursing combined with wet healing therapy
Study: 27775810
Drug: Traditional method
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional method of treatment for pressure ulcer
Study: 30989175
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic therapy
Study: 24589954
Drug: Intramuscular antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular antibiotic therapy
Study: 16185404
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeding of 50 g/L glucose normal saline (GNS) 500 ml per day containing L‐Arg (400 mg/kg.day) for 4 days (Group A)
Study: 16185404
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeding with only 50 g/L GNS 500 ml per day for 4 days (Group C)
Study: 11101479
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols from rice bran oil (2.1 g/d)
Study: 11101479
Drug: Triterpene alcohols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triterpene alcohols from sheanut oil (2.6 g/d)
Study: 8646143
Drug: Active cream
Normalized name: NIACINAMIDE 2 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL CREAM [INCELLDERM ACTIVE CREAMEX]
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active cream containing aminophylline 3%, isosorbide dinitrate 0.25%, and co-dergocrine mesylate 0.05% for one week
Study: 1550073
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg Ca/d)
Study: 28611098
Drug: Ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor and eptifibatide bolus with 2-hour infusion
Study: 23250568
Drug: L-NMMA (NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (NOS inhibition)
Study: 23250568
Drug: L-NMMA +
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA + ketorolac (combined intervention)
Study: 23250568
Drug: Ketorolac +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac + L-NMMA (combined intervention)
Study: 21242235
Drug: Disease activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease activity score-driven therapy (tight control group)
Study: 17016601
Drug: 5-FU-based adjuvant
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU-based adjuvant chemotherapy
Study: 10694831
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg)
Study: 10694831
Drug: Trandolapril (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2-4 mg)
Study: 9219787
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with 5-ASA tablets 1.6 g/day and 5-ASA enemas 4 g/100 ml twice weekly
Study: 9219787
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy with 5-ASA tablets 1.6 g/day and placebo enemas/twice weekly
Study: 28956697
Drug: AppleMets (AMS)
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AppleMets (AMS) nutraceutical formulation containing procyanidin B2 from Annurca apples
Study: 24991933
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen therapy (NOT) at 3 L/min
Study: 24991933
Drug: Acetazolamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (2 × 250 mg tablets)
Study: 24366914
Drug: Placebo (sham-NOT/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham-NOT/placebo tablets)
Study: 18284860
Drug: Intranasal amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal amphotericin B (AMB) irrigation (20 mg of AMB in 500 mL of normal saline) for 4 weeks
Study: 18284860
Drug: Placebo (yellowish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (yellowish dye in 500 mL of normal saline) for 4 weeks
Study: 18284860
Drug: Intranasal amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal amphotericin B (AMB) irrigation
Study: 18284860
Drug: Intranasal amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal amphotericin B (AMB) irrigation and Placebo
Study: 9104516
Drug: bupivacaine 0.10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.10% and 1 mg.ml‐1 meperidine (0.10% group)
Study: 9104516
Drug: bupivacaine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.05% and 1 mg.ml‐1 meperidine (0.05% group)
Study: 9104516
Drug: 1 mg.ml‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.ml‐1 meperidine (0% group)
Study: 8026249
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg erythromycin
Study: 8026249
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg erythromycin
Study: 15191881
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 mg/kg)
Study: 8026249
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg/kg)
Study: 2784233
Drug: 1000 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ppm sodium fluoride and MFP formulations
Study: 2784233
Drug: Anticalculus agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticalculus agents (HEBP and AHBP)
Study: 31508924
Drug: HIFU hemi-ablation
Normalized name: risedronate sodium hemi-pentahydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU hemi-ablation and concomitant short-term androgen deprivation therapy (ADT)
Study: 28370340
Drug: P2B001 (0.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2B001 (0.6 mg pramipexole/0.75 mg rasagiline)
Study: 28370340
Drug: P2B001 (0.3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2B001 (0.3 mg pramipexole/0.75 mg rasagiline)
Study: 28370340
Drug: Responder analysis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Responder analysis for P2B001 (0.6/0.75 mg)
Study: 28370340
Drug: Responder analysis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Responder analysis for P2B001 (0.3/0.75 mg)
Study: 17637268
Drug: ADV +
Normalized name: Black Catechu Wood/Chinese Skullcap/Chondroitin Sulfate Sodium/Dimethyl Sulfone/Glucosamine Hydrochloride/Hyaluronic Acid 66.667 MG-500 MG-500 MG-1.1 MG Oral Tablet [FOSTER&THRIVE GLUCOSAMINE CHONDROITIN ADV +MSM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV + LAM (10 mg/d ADV and 100 mg/d LAM for 12 weeks, followed by 10 mg/d ADV for 36 weeks)
Study: 17637268
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + LAM (placebo and 100 mg/d LAM for 12 weeks, followed by 10 mg/d ADV for 36 weeks)
Study: 17637268
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms after 36 weeks of therapy
Study: 9830787
Drug: High daily
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High daily dose of angiotensin-converting enzyme (ACE) inhibitors
Study: 9830787
Drug: Low daily
Normalized name: SODIUM FLUORIDE 2.43 mg in 1 g DENTAL PASTE, DENTIFRICE [Auraglow Daily]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low daily dose of angiotensin-converting enzyme (ACE) inhibitors
Study: 2292532
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 200 mg bd
Study: 2292532
Drug: Co-amoxiclav 500
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 500 mg/125 mg tds
Study: 27353505
Drug: blisibimod (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: blisibimod (200 mg QW)
Study: 17044770
Drug: Tomato drink
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato drink (250 ml)
Study: 2060566
Drug: Doxorubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50 mg/m2 as an iv bolus) administered at 21.00 h
Study: 2060566
Drug: Doxorubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50 mg/m2 as an iv bolus) administered at 09.00 h
Study: 6340496
Drug: Hydrocortisone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (2 mg/kg bolus, then 0.5 mg/kg per hour for 24 hours)
Study: 25672376
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and chemotherapy
Study: 30124724
Drug: Halobetasol propionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion
Study: 20347511
Drug: Alendronate, 70
Normalized name: Alendronate, 70 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 70 mg, administered weekly (n = 25)
Study: 18585542
Drug: Olanzapine orally
Normalized name: Olanzapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine orally disintegrating tablet (OLZ‐ODT)
Study: 18585542
Drug: Risperidone oral
Normalized name: risperidone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone oral solution (RIS‐OS)
Study: 12453852
Drug: vinorelbine-cisplatin (NP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine-cisplatin (NP; vinorelbine 30 mg/m(2) on days 1, 8 and 15 with cisplatin 80 mg/m(2) on day 1)
Study: 12453852
Drug: vinorelbine-ifosfamide-cisplatin (NIP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine-ifosfamide-cisplatin (NIP; vinorelbine 25 mg/m(2) on days 1 and 8, ifosfamide 3 g/m(2) on day 1 and cisplatin 75 mg/m(2) on day 1)
Study: 6725040
Drug: Radiosensitizing drug
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiosensitizing drug in radiotherapy
Study: 29790614
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus rhamnosus and Enterococcus faecium)
Study: 24032706
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous heparin infusion (8 U/kg/hr progressing to 10 U/kg/hr over 36 hours) starting 12 hours after surgery until Day 14
Study: 24032706
Drug: Conventional subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subcutaneous heparin twice daily as deep vein thrombosis prophylaxis
Study: 20205099
Drug: Levothyroxine (LT(4))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (LT(4)) treatment for one year
Study: 20205099
Drug: Iodine treatment
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine treatment only (Control)
Study: 14711190
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day atorvastatin for 3 months
Study: 14711190
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day atorvastatin for 3 months
Study: 10781354
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in community hospitals (group A)
Study: 10781354
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy during transportation to angioplasty (group B)
Study: 10781354
Drug: Immediate transportation
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate transportation for primary angioplasty without pre-treatment with thrombolysis (group C)
Study: 2056455
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate rinsing (15 ml b.i.d.)
Study: 2056455
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water rinsing (15 ml b.i.d.)
Study: 6352046
Drug: Timed-release dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-release dihydroergotamine preparation 10 mg/per os/day
Study: 30992295
Drug: 2-week antibiotic
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week antibiotic therapy
Study: 30992295
Drug: 4-week antibiotic
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week antibiotic therapy
Study: 21159841
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg sc every 6 months
Study: 27270237
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid 5 mg iv once
Study: 24570297
Drug: Medication Monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication Monitoring and Optimization (MeMO) intervention, comprising continuous monitoring and tailored counseling sessions, N = 495
Study: 22050030
Drug: Methamphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (0, 12, 50 mg/70 kg)
Study: 22050030
Drug: d-amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0, 12, 50 mg/70 kg)
Study: 11958805
Drug: Alcohol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.7 g/kg body mass) given 1 h after exercise
Study: 11958805
Drug: Alcohol-free solution
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-free solution administered 1 h after exercise
Study: 16256705
Drug: R(+)‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers administered orally and intravenously at a single dose of 200 mg rac‐TA.
Study: 2495910
Drug: Intravenous rtPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rtPA (total dose, 100 mg over 3 h)
Study: 699627
Drug: Diflunisal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (500 mg) twice daily
Study: 699627
Drug: Dextropropoxyphene (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene (65 mg) plus paracetamol (650 mg) 3-times daily
Study: 28562271
Drug: Perceived barriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived barriers (e.g., lack of knowing what to do in the event of pandemic influenza)
Study: 26999839
Drug: ABNS+SS (Allergen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABNS+SS (Allergen Blocking Nasal Spray + Seawater Spray)
Study: 26999839
Drug: SS (Seawater
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS (Seawater Spray)
Study: 19568030
Drug: Unstable surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstable surface balance training (air-filled rubber disks, 5 weeks, thrice weekly sessions)
Study: 14653285
Drug: Ultra‐Etch 35%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra‐Etch 35% phosphoric acid gel
Study: 14653285
Drug: Ultra‐Etch AB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra‐Etch AB 35% phosphoric acid gel with cetylpyridinium chloride antimicrobial agent
Study: 14653285
Drug: Ultra‐Etch 35%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra‐Etch 35% phosphoric acid gel followed by Concepsis chlorhexidine gluconate antimicrobial solution
Study: 14653285
Drug: Ultra‐Etch 35%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra‐Etch 35% phosphoric acid gel followed by Consepsis Scrub chlorhexidine gluconate antimicrobial slurry
Study: 14653285
Drug: No etchant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No etchant and/or cavity pre‐treatment
Study: 11129093
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg/day) administered from day 15 to day 18
Study: 3890229
Drug: Lymecycline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline (300 mg bid for 7 days)
Study: 26433040
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg orally 1 hour before general anesthesia
Study: 18601757
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of ropivacaine (100 mL solution of ropivacaine in a concentration of 2 mg/mL) (Group A)
Study: 18601757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravesical instillation and subepithelial injection of 2 mL (4 mg) at the site of biopsy (Group B)
Study: 11470347
Drug: Quintuple buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quintuple buprenorphine dosing (5x daily maintenance dose)
Study: 11470347
Drug: Sextuple buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sextuple buprenorphine dosing (6x daily maintenance dose)
Study: 9347651
Drug: Standardized ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized ginseng extract 150 mg per capsule, 2 capsules daily for 8 weeks
Study: 27884916
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical treatments (tranexamic/mefenamic acid, combined oestrogen-progestogen, or progesterone alone)
Study: 22682988
Drug: Treatment-as-usual (N=10)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (N=10)
Study: 17053895
Drug: Artemether and
Normalized name: artemether and lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether and lumefantrine (AL) treatment
Study: 12837873
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FP) 200 microg/day for 6 weeks
Study: 10717490
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT, conjugated equine estrogen 0.625 mg orally daily)
Study: 10717490
Drug: Combined estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen and continuous progestogen therapy (HRT, 0.625 mg of conjugated equine estrogens plus medroxyprogesterone acetate 5 mg daily)
Study: 8856585
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine sulfate (0.04 mg/kg/day, increased by 0.01 mg/kg/day until vomiting ceased)
Study: 8856585
Drug: Oral atropine
Normalized name: atropine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atropine sulfate (twice the effective intravenous dose) continued for 2 weeks after intravenous treatment
Study: 8856585
Drug: Ultrasonography after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonography after intravenous atropine treatment
Study: 8856585
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine sulfate
Study: 30864528
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs (NADs)
Study: 30044293
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of oral hypoglycemics (OHDs)
Study: 30044293
Drug: Withholding oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding oral hypoglycemics (OHDs)
Study: 24690440
Drug: Core vitrectomy
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core vitrectomy additional to three times injections of ranibizumab (3x Rbz)
Study: 20104770
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine 10 microg each time (group A)
Study: 17502347
Drug: Refrigerator-stable formulation
Normalized name: Refrigerant 114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refrigerator-stable formulation of ProQuad
Study: 17502347
Drug: Frozen formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen formulation of ProQuad
Study: 14969836
Drug: IFN 3
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 3 MIU daily for 4 weeks, followed by tiw up to 12 months
Study: 14969836
Drug: IFN 3
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 3 MIU daily for 12 weeks, followed by tiw up to 12 months
Study: 11675061
Drug: LY334370 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY334370 20 mg
Study: 11675061
Drug: LY334370 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY334370 60 mg
Study: 11675061
Drug: LY334370 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY334370 200 mg
Study: 3035849
Drug: Naloxone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (100 micrograms/kg bolus followed by 50 micrograms X kg‐1 X h‐1 infusion)
Study: 3035849
Drug: Control (corresponding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (corresponding volume of preservatives as bolus followed by infusion of diluted preservatives)
Study: 24091306
Drug: Short-term psychotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychotherapy (solution-focused or short-term psychodynamic)
Study: 20869680
Drug: Sonographically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonographically guided ACJ injections
Study: 20869680
Drug: Palpation-guided ACJ
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided ACJ injections
Study: 14628190
Drug: Zydis Selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zydis Selegiline 10 mg